De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Fortress Biotech Toekomstige groei

Future criteriumcontroles 2/6

De winst van Fortress Biotech zal naar verwachting dalen met 16.4% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 27.8% per jaar. De winst per aandeel zal naar verwachting groeien met 10.9% per jaar.

Belangrijke informatie

-16.4%

Groei van de winst

10.9%

Groei van de winst per aandeel

Biotechs winstgroei	34.8%
Inkomstengroei	27.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	24 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:CNB0 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	174	-61	N/A	N/A	2
12/31/2025	141	-64	N/A	N/A	3
12/31/2024	80	-55	N/A	N/A	3
6/30/2024	83	-49	-100	-99	N/A
3/31/2024	85	-63	-113	-110	N/A
12/31/2023	85	-69	-136	-128	N/A
9/30/2023	62	-87	-150	-141	N/A
6/30/2023	63	-104	-176	-168	N/A
3/31/2023	64	-100	-182	-176	N/A
12/31/2022	76	-95	-202	-179	N/A
9/30/2022	78	-97	-196	-170	N/A
6/30/2022	82	-93	-181	-149	N/A
3/31/2022	81	-74	-179	-142	N/A
12/31/2021	69	-65	-133	-117	N/A
9/30/2021	64	-38	-113	-98	N/A
6/30/2021	53	-33	-110	-101	N/A
3/31/2021	44	-43	-89	-83	N/A
12/31/2020	46	-47	-91	-84	N/A
9/30/2020	43	-57	-99	-88	N/A
6/30/2020	43	-54	-92	-81	N/A
3/31/2020	43	-54	-102	-92	N/A
12/31/2019	37	-40	-104	-95	N/A
9/30/2019	34	-45	-98	-92	N/A
6/30/2019	30	-51	-106	-101	N/A
3/31/2019	27	-53	-105	-96	N/A
12/31/2018	27	-73	-108	-99	N/A
9/30/2018	-107	-61	-107	-98	N/A
6/30/2018	-65	-69	-105	-98	N/A
3/31/2018	-22	-72	N/A	-98	N/A
12/31/2017	17	-65	N/A	-81	N/A
9/30/2017	155	-74	N/A	-78	N/A
6/30/2017	109	-60	N/A	-62	N/A
3/31/2017	61	-55	N/A	-46	N/A
12/31/2016	16	-55	N/A	-46	N/A
9/30/2016	4	-50	N/A	-35	N/A
6/30/2016	3	-55	N/A	-31	N/A
3/31/2016	1	-49	N/A	-30	N/A
12/31/2015	1	-48	N/A	-20	N/A
9/30/2015	1	-40	N/A	-17	N/A
6/30/2015	1	-27	N/A	-14	N/A
3/31/2015	1	-25	N/A	-12	N/A
12/31/2014	N/A	-20	N/A	-16	N/A
9/30/2014	N/A	-26	N/A	-20	N/A
6/30/2014	N/A	-30	N/A	-24	N/A
3/31/2014	N/A	-36	N/A	-28	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CNB0 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CNB0 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CNB0 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CNB0 ( 27.8% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van CNB0 ( 27.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CNB0 naar verwachting over 3 jaar hoog zal zijn

Fortress Biotech Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven